Home › Blog › Q&A › NAD+, CD38 & Age-Related Decline

What Is CD38 and How Does It Relate to Age-Related NAD+ Decline?

Published 2026-07-13 · REVIVE Peptides Research Desk · 1 min read

Short answer: CD38 is the major NAD+-consuming enzyme in the body, and its activity increases with age — a documented contributor to why cellular NAD+ levels decline progressively over a lifetime, typically reduced by 50% or more by age 60 compared to young adults.

NAD+ research on aging centers heavily on a simple observed pattern: cellular NAD+ availability declines steadily as people get older, and CD38 is one of the most-studied enzymes responsible for consuming that NAD+ supply. As CD38 activity increases with age, it directly competes with sirtuins and PARP enzymes for the same limited NAD+ pool.

This is one of the central reasons NAD+ decline is studied as a unifying thread across multiple aging-related research areas — mitochondrial bioenergetics, DNA repair capacity, and sirtuin signaling are all affected by the same underlying NAD+ availability problem, and CD38's age-related increase is a documented driver of that decline.

This describes published research literature on NAD+ and CD38 biology, provided for research background only — not a therapeutic claim.

NAD+ 100 mg — REVIVE LAB UAE
Purity ≥ 99.0% (HPLC) · COD, card or Binance Pay (5% off) Order NAD+ UAE — Live Stock & Pricing

Research-Use Only Disclaimer: This page is published for laboratory and scientific research information purposes only. Nothing here constitutes medical advice, dosing guidance, or a therapeutic recommendation. Products supplied by REVIVE LAB UAE (revivelab.ae) — where applicable — are sold strictly as reference materials for research use, not for human or veterinary consumption. Buyers and readers are solely responsible for compliance with applicable UAE laws and institutional research ethics requirements.

What Is CD38 and How Does It Relate to Age-Related NAD+ Decline?

Related Questions